Special premium report Part 1: My 2018 earnings boom profit strategy–and two picks

Special premium report Part 1: My 2018 earnings boom profit strategy–and two picks

With the report of first quarter earnings season from Netflix (NFLX) on Monday, April 16, we’ve moved into the heart of earnings season. In most quarters traders began putting on plays for earnings announcements a few weeks before reporting starts. And they’ll keep making new bets over the next three weeks or so. In most quarters buying shares or options on companies about to report makes profitable sense. But this strategy is likely to be even more rewarding this year

New calculation: Current cash position in Jubak Picks Portfolio

New calculation: Current cash position in Jubak Picks Portfolio

In response to reader requests from here on out I’m going to calculate an approximate cash position (I won’t do all the nitty gritty to include things like the latest dividend payouts but the number should be reasonably close) after each buy and sell. The latest action in the portfolio was the April 3, 2018 sell of Freeport McMoRan Copper & Gold. After that sale the cash position in the portfolio is 31.6%. That’s up from 27.2% at the end of December 2017.

Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash

Turning around the Jubak Picks portfolio: It takes time (frustrating amounts of time) but by late 2016 the recovery was in place: 2017 total return 13.13% despite 27.2% cash

Turning around a portfolio can take a frustratingly long time. The Jubak’s Picks portfolio has had a performance problem since 2014. But I think I’ve finally put a recovery in place. The total return on the portfolio was 13.1% in 2017. That still badly lagged the 21.7% total return on the Standard & Poor’s 500. But it’s promising–considering that the portfolio finished the year 27.2% in cash. (Which itself was better than the 37% cash at the end of 2016.)

FDA sets next date for Incyte arthritis drug, baricitinib

Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug

In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo